Accueil   Diary - News   All news ImmunID Strengthens its Intellectual Property Position in China

ImmunID Strengthens its Intellectual Property Position in China

ImmunID Strengthens its Intellectual Property Position with
the Issuance of a Key Technology Patent in China

 

ImmunID, the immune companion diagnostics company, today announced the granting of a key patent in China. This patent (WO 2009095567) covers the multi-N-plex® Polymerase Chain Reaction (PCR) technology underlying the ImmunTraCkeR® and ImmunIG® assays. ImmunTraCkeR® and ImmunIG® evaluate a patient’s own immune status, based on T cell repertoire diversity and B cell repertoire diversity, respectively. ImmunTraCkeR® has demonstrated clinical utility predicting response to cancer immunotherapy and is currently under further validation in the Predict-ID program for prediction of response and monitoring of cancer patients under treatment with immune checkpoint inhibitors.

 

Read the press release